Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma)
Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) expects the company to maintain its growth trajectory and long-term value creation.
“We are tracking well towards our revenue guidance of CAGR of 12–15% achieving a YTD growth of 13%. As for our EBITDA margin, we upgrade our target range to 34-34.5% from 31.5-33%, supported by the strong PL performance seen in 2025,” he said, in an interview with Argaam.
Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma)
Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) expects the company to maintain its growth trajectory and long-term value creation.
“We are tracking well towards our revenue guidance of CAGR of 12–15% achieving a YTD growth of 13%. As for our EBITDA margin, we upgrade our target range to 34-34.5% from 31.5-33%, supported by the strong PL performance seen in 2025,” he said, in an interview with Argaam.
